Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study.

被引：0

作者：

Xu, Yongkang ^{[1
]}

Fu, Shumin ^{[1
]}

Mao, Ye ^{[1
]}

Yi, Fengming ^{[1
]}

Jiang, Weiming ^{[1
]}

Feng, Long ^{[1
]}

Wu, Jianbing ^{[1
]}

机构：

[1] Nanchang Univ, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

298-145-222-184-4809-5347; 281-5277-2622-5397; 281-5277-6771; 261-492-2769; 3282-3306-3348-4026; 283-2494; 613-135-244-3829-325; 3; 2; 28; 2424; 54; 239; 193; 1700; 4; 1; 38092-32104; 38116-38094-8;

D O I：

10.1200/JCO.2024.42.3_suppl.500

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：500 / 500

页数：1

共 50 条

[41] Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study
Guo, Wenbo
Gao, Jian
Zhuang, Wenquan
Wu, Zhiqiang
Li, Bin
Chen, Song
JGH OPEN, 2020, 4 (03): : 477 - 483
[42] Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion
Zhang, Yufeng
Zhang, Haiyan
Xu, Haoqian
Wang, Ying
Feng, Long
Yi, Fengming
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
[43] TACE combined with the intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: A prospective, single-arm, phase II study
Mu, Maoyuan
Fu, Xiaobo
Qi, Han
Jiang, Weiwei
Chen, Zixiong
Gao, Fei
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[44] Postoperative adjuvant hepatic arterial infusion chemotherapy combined with donafenib in hepatocellular carcinoma with solitary large tumor and microvascular invasion: A multicenter, prospective, single-arm, phase II trial
Long, Yin
Huang, Ziqi
He, Xiaodong
Huang, Jue
Liao, Jianguo
Zeng, Yongyi
Tang, Yunqiang
Zhang, Lei
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[45] Donafenib combined with camrelizumab and transarterial chemoembolization (TACE) as conversion therapy for unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm, phase II study.
Cao, Yajuan
Zhang, Xuebin
Yue, Yang
Peng, Jin
Li, Binghua
Shi, Jiong
Tang, Min
Chen, Chaobo
Su, Ke
Zhang, Laizhu
Cheng, Chunxiao
Yu, Decai
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[46] Hepatic artery infusion chemotherapy combined with donafenib and camrelizumab in patients with unresectable hepatocellular carcinoma presenting portal vein tumor thrombus: A prospective, single-arm study
He, Qiang
Wu, Chenrui
Pan, Long
Li, Jiachu
Zhou, Yin
Cao, Hongxiang
Sun, Ruirui
Huang, Junjie
Wang, Yongchen
Huang, Ping
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] Camrelizumab combined with apatinib and hepatic artery infusion chemotherapy (HAIC) as conversion therapy for patients with unresectable hepatocellular carcinoma(HCC): A single-arm exploratory clinical study
Zhao, Lei
Zhang, Bo
Shi, Xuetao
Cui, Kai
Zhang, Jianxin
Zhong, Jingtao
Li, Zhongchao
Sun, Pengfei
Zhang, Chengsheng
Li, Lei
CANCER RESEARCH, 2024, 84 (06)
[48] Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Li, Z.
Li, L.
Cui, K.
Zhong, J.
Sun, P.
Zhang, C.
Shi, X.
ANNALS OF ONCOLOGY, 2023, 34 : S597 - S597
[49] Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma
Xu, Yongkang
Fu, Shumin
Mao, Ye
Huang, Shenglan
Li, Dan
Wu, Jianbing
FRONTIERS IN MEDICINE, 2022, 9
[50] Stereotactic body radiation therapy combined with chemotherapy and tislelizumab in metastatic nasopharyngeal carcinoma: A prospective, single-arm, phase II study
Liu, T.
Tao, C.
Qin, W.
Jiang, F.
ANNALS OF ONCOLOGY, 2024, 35 : S632 - S633

← 1 2 3 4 5 →